<DOC>
	<DOCNO>NCT02451527</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetic study combination digoxin polythylene glycol loxenatide injection ( PEX168 ) healthy adults，and provide scientific basis clinical combination PEX168 drugs.This study also evaluate safety tolerability mono-digoxin digoxin plus PEX168 .</brief_summary>
	<brief_title>The Pharmacokinetic Study Combination Digoxin Polythylene Glycol Loxenatide Injection Healthy Subjects</brief_title>
	<detailed_description>This open-label , single-arm , sequential , single-center clinical trial . 16 healthy male admit clinical facility Day -1 , day prior start dosing . The subject observe clinic twice : Day -1 8 Day 37 44 . Subjects receive single dose digoxin Day 1 follow 5 weekly subcutaneously injected dos PEX168 second single dose digoxin Day 38 . To determine pharmacokinetic parameter digoxin drug administration alone multiple dos PEX168 , blood urine sample collect dose digoxin test laboratory.The subject discharge Day 8 Day 44 . Approximately 28 day last discharge , subject call post study visit .</detailed_description>
	<mesh_term>Digoxin</mesh_term>
	<criteria>1 . Healthy male age 18 45 year 2 . Have body weight 50kg , body mass index ( BMI ) 1925 kg/m^2 ( inclusive ) 3 . Alanine aminotransferase &lt; 50 U/L , aspartate aminotransferase &lt; 50 U/L , alkaline phosphatase total bilirubin &lt; 1.5x upper limit normal 4 . According CockcroftGault , estimate Clcr≥90ml/min 5 . Able comprehend willing sign inform consent form 1 . Hepatitis B surface antigen ( + ) ， Hepatitis C virus antibody ( + ) ，AIDS antibody（+） 2 . History syncope , palpitation , bradycardia tachycardia ( example degree atrioventricular block , leave bundle branch block , right bundle branch block ) , abnormal result overall physical examination ( vital sign , physical examination ) , routine laboratory assessment ( hematology , biochemistry urinalysis ) , 12lead ECG abdominal sonography ( liver , gallbladder , pancreas , spleen , kidney ) 3 . Have alcohol substance abuse within 6 month screen 4 . History smoking within 3 month screen 5 . BP &gt; 140/90 millimetre mercury , heart rate &gt; 100 bpm 6 . QT interval &gt; 450ms 7 . History druginduced allergy hypersensitivity digoxin PEX168 8 . History serious heart disease lung disease 9 . Fasting triglyceride &gt; 1.5x upper limit normal 10 . Subjects liver disease history liver disease abnormal liver gallbladder condition 11 . Donation blood excess 400 mL within 3 month screen ; donation blood within 1 month screening ; receive blood transfusion within 1 month screening . 12 . Hypothyroidism 13 . Surgery gastrointestinal tract 14 . History pancreatitis 15 . History cholecystitis gallbladder disease 16 . History inflammatory bowel disease irritable bowel syndrome 17 . History MEN type 2 syndrome 18 . History medullary thyroid carcinoma 19 . A family history MEN type 2 syndrome medullary thyroid carcinoma 20 . Have participate clinical trial drug medical device involve within 3 month screen 21 . Have receive drug may affect study drug within 2 week screen , include prescribe drug , overcounted drug , Chinese traditional medicine multivitamins 22 . History grapefruit juice , cranberry , mango , food drink xanthine caffeine , strenuous exercise , factor affect absorption , distribution , metabolism excretion study drug within 2 day screen 23 . Have receive glucagonlike peptide1 mimetic compound ( e.g. , exenatide ) 24 . Have disagree use reliable method birth control study 6 month follow last dose study drug 25 . History condition , opinion investigator , may prevent subject follow completing protocol</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>